pbyi-10k_20171231.htm
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Inc (PBYI) Stock Message Board | InvestorsHub
Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?
Puma Biotechnology: Cheap But Quite Risky (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology unveils Phase II breast cancer trial design
Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth
Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates | Nasdaq
Is This Low-Priced Biotech Stock a Hidden Gem? - TheStreet's Real Money Pro
Marcus Morreale - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology, Inc. (PBYI): history, ownership, mission, how it works & makes money
EX-99.1
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotech anti-HER2 breast cancer drug approved in China - BioTuesdays
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Inc Company Profile - GlobalData
Puma Biotechnology begins Phase II trial of lung cancer drug
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity | Market Exclusive
Puma Biotechnology, Inc. (PBYI) BCG Matrix Analysis
Puma Biotechnology: Profitable, Troubled, But Worth A Good Look (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
